BMRA logo

BIOMERICA INC

BMRANASDAQ
🏆 #5091 by market capEarnings Oct 21US Equity
$2.32▼ $0.01 (−0.22%)
After hours · at close
🔔
Track BMRA
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.2%
7d▼ 15.2%
14d▼ 1.1%
30d▲ 8.4%
ytd▼ 7.4%
1y▼ 18.8%
🏦Market Cap
$7M
Small Cap
📈Revenue Growth (YoY)
-16.2%
Declining
📊Gross Margin
8.1%
Thin
💵FCF Margin
-77.7%
Thin
⚖️P/S Ratio
1.6x
Cheap
Otter Score
60
Fair

Trading Snapshot

Day Range
$2.30 – $2.34
52-Week Range
$1.45 – $3.21
Volume
$2.84B
Avg Volume
$3.17B
Shares Outstanding
3.1M
Next Earnings
Dec 11, 2026

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$875,000
P/E Ratio
-1.8
P/S Ratio
1.6x
EPS (TTM)
$-1.23
Dividend Yield
0.00%
Dilution (1yr)
+5.6%

Why Investors Own BMRA

  • ✓High-growth profile — revenue up +49.5% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 29% gross margin and 21% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

BMRA logo

BIOMERICA INC

BMRA
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$4M▼ −16.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
8.1%▼ −13.3% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$5M▲ +3.6% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$3M▼ −11.8% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
3.1M▲ +5.6% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$575K▼ −$3M YoY
StockOtter · stockotter.space

About BIOMERICA INC

Biomerica, Inc. is a biomedical technology firm that invents, secures intellectual property for, produces, and globally distributes diagnostic and therapeutic solutions aimed at identifying and addressing a range of medical conditions and diseases. The company's diagnostic testing kits analyze patient samples, such as blood, urine, or stool, to pinpoint various illnesses and health complications. These kits are also capable of quantifying minute concentrations of specific substances like bacteria, hormones, antibodies, antigens, or other compounds present in bodily fluids or waste. Biomerica primarily sells its products for gastrointestinal disorders, food sensitivities, diabetes, and a variety of specialized diagnostic evaluations. Its distribution channels include physicians' clinics, retail pharmacies, and hospital/clinical laboratories. The company is currently developing InFoods, a diagnostic-guided therapy technology for irritable bowel syndrome; products for Helicobacter pylori; and comprehensive diagnostic tools for COVID-19, encompassing their development, testing, validation, and sale. Established in 1971, Biomerica, Inc. maintains its corporate headquarters in Irvine, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
60/100

Analyst Price Target

ⓘ
Average Target
$2.51
▲ +8.6% Upside
High Target$2.73
Low Target$1.90
Based on 23 analysts

Latest News & Updates

🚀
MarketWatch·2h ago

BIOMERICA INC tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
Bloomberg·5h ago

Analysts lift BMRA price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
CNBC·1d ago

BIOMERICA INC announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.